IJPSR (2010), Vol. 1, Issue 6



Received 24 March, 2010; received in revised form 15 May, 2010; accepted 25 May, 2010

ANTI-DIABETIC ACTIVITY OF *PSORALIA CORYLIFOLIA* SEED EXTRACT IN ALLOXAN INDUCED DIABETIC RATS

Anurag Mishra*, Rajiv Gupta and Rahul Dev Lawania

Department of Pharmacognosy, Faculty of Pharmacy, Babu Banarasi Das National Institute of Technology and Management, Lucknow, (U P) India

Keywords:

Diabetes mellitus, Psoralia corylifolea Glucose, Metformin, Alloxan

*Correspondence for Author

ANURAG MISHRA

Department of Pharmacognosy, Faculty of Pharmacy, Babu Banarasi Das National Institute of Technology and Management, Lucknow, (U P) India

Email: anupriya0522@yahoo.co.in

ABSTRACT

Psoralia corylifolia commonly known as Babchi, Bavachi in Hindi, is a well known herb in Indian system of medicine to treat various disorders including diabetes mellitus without any scientific evidences. Therefore this study was designed to investigate in vivo hypoglycemic and antidiabetic potential of methanolic extract of seeds of Psoralia corylifolia in glucose loaded animals and alloxan induced diabetic animals. In both the models Psoralia corvlifolia reduced the blood glucose level when compared to diabetic control group and exert a significant hypoglycemic and antidiabetic activity. However the potency of the herb was less than that of standard drug metformin. Psoralia corylifolia methanolic extract also reversed the body weight in normal and alloxan induced diabetic animals. The results of this study revealed the presence of a significant antidiabetic potential of methanolic extract of Psoralia corvlifolia in alloxan induced diabetic rats. On the basis of this further research work is needed to investigate exact mechanism of action and also to isolate the active constituent/s responsible for the activity.

INTRODUCTION: Diabetes mellitus (DM) currently is a major health problem for the people of the world and is a chronic metabolic disorder/syndrome resulting from a variable interaction of hereditary and environmental factors and is characterized by abnormal insulin secretion or insulin receptor or post affecting metabolism receptor events involving carbohydrates, proteins and fats in addition to damaging liver, kidney and β cells of pancreas¹. The number of people suffering from the disease worldwide is increasing at an alarming rate with a projected 366 million peoples likely to be diabetic by the year 2030 as against 191 million estimated in 2000². From literature review it has been revealed that 15 - 20% of diabetic patients are suffering from insulin-dependent diabetes mellitus (IDDM) or type-I 3 .

The IDDM is noted both in adult and child hood. It is characterized by elevation of both fasting and post-prandial blood sugar levels. Chronic hyperglycemia during diabetes causes glycation of body proteins that in turn leads to secondary complications affecting eyes, kidneys, nerves and arteries ^[4]. These may be delayed, lessened or prevented by maintaining blood glucose values close to normal in modern medicine; no satisfactory effective therapy is still available to cure the diabetes mellitus. Though insulin therapy is also used for the management of diabetes mellitus, but there are several drawbacks like insulin resistance ⁵, anorexia nervosa, brain atrophy and fatty liver after chronic treatment. Besides the use of insulin for the treatment of insulin dependent diabetes mellitus (IDDM), other approaches for the control of hyperglycemia include the use of amylin analogues which regulate gastric emptying and

inhibitors of intestinal alpha glucosidases like acarbose, miglitol and voglibose which delay postprandial hyperglycemia. Sulphonylureas, the most widely used class of drugs act by closure of ATP dependent channel. Metformin, a biguanide oral antidiabetic limits intestinal glucose absorption. These drugs have certain effects like causing hypoglycemia at higher doses, liver problems, lactic acidosis and diarrhoea. It is apparent that due to the side effects of the currently used drugs, there is a need for a safe agent with minimal adverse effects, which can be taken for long durations. Though biguanides and sulfonylureas are valuable in treatment of diabetes mellitus, their use is restricted by their limited action, pharmacokinetic properties, secondary failure rates and accompanying side effects ⁶. Moreover, these therapies only partially compensate for metabolic derangements seen in diabetics and do not necessarily correct the fundamental biochemical lesion ⁷.

Recently, there has been increasing interest in the use of medicinal plants. The use of medicinal plants in modern medicine suffers from the fact that though hundreds of plants are used in the world to prevent or to cure diseases, scientific evidence in terms of modern medicine is lacking in most cases. However today it is necessary to provide scientific proof as whether to justify the use of plant or its active principles⁸. The herb Psoralia corvlifolia belongs to the Leguminoseae family and is commonly known as Babchi, Bavachi in Hindi. It has a long history of use in Ayurvedic medicine (the traditional medicine system of India). The species is distributed in Arabian countries, Pakistan, Bangladesh, India, Sri Lanka, Burma China, Somalia and Scootra. It is widely

distributed in the plains of India from Uttar Pradesh to Tamil Nadu⁹. Evidence suggests that Psoralia corylifolia have anti-tumour, immunomoudulatory, anti-filarial, antileucodermal, anti-microbial, analgesic, antipyretic and anti-inflammatory activity. Psoralia corylifolia has also shown some promising speed in treatment of psoriasis, scabies & is prescribed as local & oral application to skin ¹⁰⁻ ¹⁵. *Psoralia corylifolia* is widely used as an antidiabetic agent in India and prescribed for the patient having high blood glucose level without any scientific investivgation ¹⁶. So, in the present study, we investigated the hypoglycemic and antidiabetic effect of Psoralia corylifolia seeds extract on healthy and alloxan- induced diabetic rats.

MATERIALS AND METHODS:

Plant material: The seeds of *Psoralia corylifolia* were collected from a well reputed shop of local market of Lucknow and were authenticated by division of Taxonomy, National Botanical Research Institute (NBRI), Lucknow and a voucher specimen no. NBRI/CIF/Re./08/2008/32 was deposited in national herbarium of NBRI for future reference.

Chemicals used: All chemicals and drugs were obtained from central store of Faculty of Pharmacy, BBBNITM, Lucknow and were of analytical grade.

Extraction preparation: The seeds of *Psoralia corylifolia* were dried under shade and then pulverized into moderate fine powder in a mechanical grinder and then passed through a sieve no. 44. This powdered drug was extracted with methnol in a soxhlet apparatus. The extract was filtered and concentrated

under vacuum using rota evaporator (buchi type) and stored in a dessicator for further use.

Animals: Healthy male albino Wister rats each weighing 150-200 g were used for study. The rats were housed in polypropylene cages in animal house of BBDNITM, Lucknow and maintained under standard conditions (12 h light and dark cycles, $25 \pm 3^{\circ}$ C and 55-60 % relative humidity). The animals were fed with a standard diet and water *ad libitum*. The study was performed as per the guidelines of IAEC and CPCSEA and was approved by approval no. - BBDNITM/IAEC/01/2010.

Phytochemical screening: The preliminary phytochemical screening of the crude extract of *Psoralia corylifolia* was carried out in order to ascertain the presence of its constituents utilizing standard conventional protocols ¹⁷⁻¹⁹.

Acute toxicity study: Increasing doses of various extract were given to different animals to determine change in parameters for acute toxicity and lethal dose LD₅₀. Correspondingly dose used for pharmacological activity was decided for methanolic extract ²⁰.

Induction of Diabetes Mellitus: Twenty four male Albino Wistar rats weighing 150-200 grams were used for the study of the effects of *Psoralia corylifolia* extracts on the blood glucose levels of the animals. The animals were fed on commercial feeds and were given water *ad* libitum. The animals were fasted from feeds for 12 hours before the commencement of each experiment, but were allowed water *ad libitum*. The rats were injected with alloxan tetra hydrate suspended in water at a dose of 120 mg/kg body weight intraperitonealy. They were kept for the next 24 hours on 5% glucose solution bottles in their cages to prevent hypoglycemia. After a period of three days the rats with a blood glucose levels greater than 150 mg/dl were considered diabetic and used for this research work ²¹.

Experimental Procedure for Oral Glucose Tolerance Test (OGTT) and antidiabetic activity: The animals for oral glucose tolerance test were randomly assigned into four groups of six rats in each group (n=6) each as follows, namely;

- Group 1- Normal un- diseased animals who only received normal saline (Normal Control)
- Group 2- Diseased animals which received glucose (1.75 gm /kg p. o.) (Disease control)
- Group 3- Diseased animals who first received metformin 11.3 mg/kg and then *glucose* (2 hrs. later) 1.75 gm/kg p. o. (Standard)
- Group 4- Diseased animals treated with methanolic extract of *Psoralia corylifolia*.

Oral glucose tolerance tests were performed on 16 hr fasted Wister rats using 1.75 gm glucose per kg body weight fed orally (dissolved in water for injection) through a canula fitted needle attached to syringe. Just after glucose fed single dose of plant sample (methanolic extract of seeds of Psoralia corylifolia) were also fed to study the effect of the same on GTT. The control group was fed equal amount of vehicle solution orally ²¹. In all the groups, blood was collected from the animal's tail vein at 0, 30, 60, 90 minutes after glucose feeding. Simultaneously, blood glucose was measured by trinder's glucose oxidase method using spectrophotometer. The animals for Alloxan-induced diabetic study

were randomly assigned into four groups (I-IV) of six rats (n=6) each as follows, namely;

- Group 1- Received normal saline orally
- Group 2- Diseased animals who received glucose (1.75 gm /kg p.o.) Diseased control
- Group 3- Diseased animals who first received metformin 11.3 mg/kg and then glucose (2hrs. later) 1.75 gm/kg p. o. (standard)
- Group 4- Diseased animals treated methanolic extract of *Psoralia corylifolia* mg/kg²¹.

Determination of blood glucose levels: Blood samples were collected by cutting the tail-tip of the rats, for blood glucose determination at intervals of 1st, 7th, 14th and 21st day. Determination of the blood glucose level was done by the glucose-oxidase principle using the ONE TOUCH Basic (Lifescan, Milpitas, CA) instrument and results were reported as mg/dl.

Statistical analysis: Blood glucose levels were expressed in mg/dl as mean ± SEM. The data were statistically analyzed using ANOVA with multiple comparisons versus disease control group. The values of P<0.05 and P<0.01 were considered as significant.

RESULTS:

Phytochemical analysis: Freshly prepared extracts were subjected to preliminary phytochemical screening test for various constituents. This revealed the presence of tannins, carbohydrate, terpenes, saponins, flavonoids and alkaloids.

Pharmacological Screening:

Determination of acute toxicity and LD₅₀ **values:** After using various dose levels in various groups the toxicological data and LD_{50} values was determined for methanol extract. No mortality was seen upto dose as high as 2 gm/kg body weight by Staircase method. So dose well below the possibly toxic (approximately $1/10^{th}$) of 2 g/kg body weight was taken ie. 200 mg/kg body weight dose was taken.

DISCUSSION AND CONCLUSION: This study firstly evaluated the hypoglycemic effect of Psoralia corylifolia in glucose induced hyperglycemia and alloxan induced diabetic rats. It was found that pretreatment of Psoralia corylifolia methanolic extract in normal rats at a dose level of 200 mg/kg body weight caused a partial prevention of hyperglycemia induced by glucose (1.75 gm/kg body weight). In alloxan induced diabetes rat Psoralia corylifolia methanolic extract showed a significant decrease in blood glucose level when treated for 21 days at a dose level of 200 mg/kg body weight.

It was also observed that Psoralia corylifolia seeds methanolic extract when administered to alloxan induced diabetic rats, the weight loss was reversed and the animal returned to near normal when compared to disease control group. The ability of the methanolic extract of seeds to protect body weight loss seems to be due to its ability to reduce hyperglycemia. The possible mechanism by which seeds bring about a decrease in blood sugar level may be by potentiation of the insulin effect of plasma by increasing either the pancreatic secretion of insulin from β cells of the islets of Langerhans or its release from the bound form. A number of other plants have been reported to exert

hypoglycemic activity through insulin releasestimulatory effect.



FIG. 1: EFFECT OF DRUG EXTRACT ON GLUCOSE TOLERANCE TEST IN NORMAL RATS



FIG. 2: EFFECT OF EXTRACT ON BLOOD GLUCOSE LEVEL IN ALLOXAN INDUCED DIABETIC RATS



FIG. 3: EFFECT OF DRUG EXTRACT ON BODY WEIGHT IN ALLOXAN INDUCED DIABETIC RATS

TABLE 1: EFFECT OF EXTRACT ON GLUCOSE TOLERANCE TEST IN NORMAL RATS

GROUPS	DOSE	BLOOD GLUCOSE LEVEL(MG/DL) (MEAN ± SEM)			
		0 MINUTE	30 MIN	60 MIN	90 MIN
Group I (normal control)		103.83 <u>+</u> 2.49	105.65±2.94	104±3.36	104.59±2.61
Group II (disease control)	1.75 g/kg	105.05±1.54	201.66±2.40	267.83±1.60	198.67±1.74
Group III (standard)	11.3 mg/kg	104.30±1.52**	115.95±1.50**	115.70±3.99**	101.5±1.23**
Group IV (Test)	200 mg/kg	109.45 <u>+</u> 2.85**	132.20±7.35**	137.46±3.56**	126.0 <u>+</u> 8.14**

Group I- normal control; Group II- Diseased control; Group III-Diseased animals treated with standard drug Metformin; Group IV-Diseased animals treated with methanol extract

Values are expressed in Mean ± SEM (n=6), P**<0.05 when compared to Group II

TABLE 2: EFFECT OF EXTRACT ON PLASMA GLUCOSE IN ALLOXAN INDUCED DIABETIC RATS

GROUP	DOSE	BLOOD GLUCOSE LEVEL (MG/DL) (MEAN ± SEM)			
		1 ST DAY	7 TH DAY	14 TH DAY	21 ST DAY
Group I (normal control)		97.62±2.72	98.56±1.77	91.92±02.18	87.34±2.18
Group II (disease control)	120 mg/kg	194.0±11.09	210.1± 7.48	235.2± 4.52	240.3± 9.82
Group III (standard)	11.3 mg/kg	167.54±3.67*	165.85±2.54*	132.20±2.47*	115.25±2.23*
Group IV (Test)	200 mg/kg	187.30±5.2**	196.55±1.7**	160.42±5.76**	142.15±6.70**

Group I- normal control; Group II- Diseased control Group III-Diseased animals treated with standard drug Metformin; Group IV-Diseased animals treated with methanol extract

Values are expressed in Mean ± SEM (n=6), P**<0.05, P*<0.01 when groups was compared to Group II

TABLE 3: EFFECT OF EXTRACT ON BODYWEIGHT OF ALLOXAN INDUCED DIABETES IN RATS

GROUPS	INITIAL BODY WEIGHT (GM <u>+</u> SEM)	FINAL BODY WEIGHT (GM <u>+</u> SEM)
Group I (normal control)	162.47±3.98	179.67±3.42
Group II (disease control)	165.24±6.74	125.87±6.67
Group III (standard)	164.34±6.45	158.23±4.98
Group IV (Test)	175.82±9.60	148.59±6.77

Group I- normal control; **Group II**- Diseased control; **Group III**-Diseased animals treated with standard drug Metformin; **Group IV**-Diseased animals treated with methanol extract of *Psoralia corylifolia*

Values are expressed in Mean ± SEM (n=6)

To our knowledge, this is the first study in which methanolic extract of seeds of *Psoralia corylifolia* was proved *in vivo* a potent hypoglycemic/anti-hyperglycemic agent and this information can be useful for the management of Type-I as well as Type-II diabetes mellitus. On the basis of this study further research works are needed to understand the exact mechanism of action of hypoglycemia produced by drug and to isolate the moieties responsible for the activity.

REFERENCES:

- 1. Baynes JW: Role of oxidative stress in development of complication of diabetes. Diabetes 1991; 40:405-12.
- Wild SG, Roglic A, Green R, King H: Global prevalence of diabetes. Estimated for the year 2000 and projection for 2030. Diabetes Care 2004; 27:1047-1054.
- Wilson JD, Foster DW, Kronenserg HM, Larson PR: Williams's Text Book of Endocrinology. WB Saunders, Philadelphia. 1998: 973–1060.
- Galadari EO, Behara I, Manchandra M, Abdulrazzaq SK, Mehra MK: Diabetes Mellitus and Its Complications: An Update. Macmillan 1993.
- Piedrola G, Novo E, Escober F, Garcia-Robles R: White blood cell count and insulin resistance in patients with coronary artery disease. Ann. Endocrinol 2001; 62: 7– 10.
- Bailey CJ, Flatt PR, Marks V: Drugs inducing hypoglycemia. Pharmacol Therapeutics 1989; 42: 361-384.
- 7. Taylor R, Agius L: The Biochemistry of diabetes. Biochem J. 1988; 250: 650–740.

- Singh RP, Padmavathi B, Rao AR: Modulatory influence of Adhatoda vasica (Justica adhatoda) leaf extract on the enzyme of xenobiotic metabolism, antioxidant status and lipid peroxidation in mice. Molecular and Cellular Biochem 2000; 213: 99-109.
- 9. Yadav SR, Kulkarni AR: Geophytology. 1986; 16 (1): 198-215
- 10. Rangari VD, Agrawal SR: Chemistry and Pharmacology of *Psoralia corylifolia*. Indian Drugs 1992; 29: 15.
- 11. Sharma NC, Nadkarani and Sheshadri: Indian Drugs. 1933; 36.
- 12. Kirtikar KR, Basu BD: Indian medicinal Plants. Oriental Enterprises, Edition 2, Vol. III, 1935: 1675.
- 13. Qamaurddin A, Praveen N, Khan N, Singhal KJ: Potent antifilarial activity of leaf and seed of *Psoralia corylifolia on* cattle filarial parasite. Journal of Ethnopharmacology 2002; 82: 23.
- 14. Latha PG, Evans DA, Panikar AR, Jayavardhan KK: Immunomodulator and antitumour property of *Psoralia corylifolia* seed. Fitoterapia 2000; 71: 223-231.
- 15. Yang YM, Hyun JW, Sung MS, Chung HS, Kim BK: The cytotoxicity of Psoralidin from seeds of *Psoralia corylifolia*. Planta Medica 1996; 62: 153-154.
- 16. Vaidya Gogte: Ayurvedic Pharmacology. 436-437.
- Harborne JB: Phytochemical Methods: A guide to modern techniques of plant analysis. Springer 1998: 40-68.
- Khandelwal KR: Practical Pharmacognosy: Techniques and Experiments. Nirali Prakashan Pune 2006: 146-161.
- 19. Mukherjee PK: Quality Control of Herbal Drugs. Business Horizons New Delhi 2002: 164–171.
- 20. Kulkarni SK: Handbook of Experimental Pharmacology. Vallabh Prakashan New Delhi 1999: 75.
- 21. Vogel GH: Drug discovery and Evaluation. Berlin Springer Verlag. 2003; 3: 950-951